Dear Mr. Abarshalin:

Please refer to your Supplemental New Drug Application (sNDA) dated December 18, 2013, received December 18, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lincocin (lincomycin hydrochloride injection, USP) Sterile Solution.

We acknowledge receipt of your amendment dated October 7, 2014.

This “Changes Being Effected” supplemental new drug application provides for the addition of a warning regarding benzyl alcohol in the WARNINGS Section and Precautions Section, Pregnancy and Pediatric Use subsections of the label and also for revisions to the CLINICAL PHARMACOLOGY Section, Microbiology subsection.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

We note that your October 7, 2014, submission includes final printed labeling (FPL) for your package insert. We have not reviewed this FPL. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling for the package insert, with the addition of
any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as
annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled
“SPL Standard for Content of Labeling Technical Qs and As at
CM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes
for this NDA, including CBE supplements for which FDA has not yet issued an action letter,
with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the
changes approved in this supplemental application, as well as annual reportable changes and
annotate each change. To facilitate review of your submission, provide a highlighted or marked-up
version that shows all changes, as well as a clean Microsoft Word version. The marked-up version
should provide appropriate annotations, including supplement number(s) and annual report
date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA
(21 CFR 314.80 and 314.81).

If you have any questions, call Carmen DeBellas, Regulatory Project Manager, at (301) 796-1203.

Sincerely,

{See appended electronic signature page}

Sumathi Nambiar, MD, MPH
Director
Division of Anti-Infective Products
Office of Anti-Infective Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
   Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SUMATHI NAMBIAR
10/15/2014